Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:46 PM
Ignite Modification Date:
2025-12-24 @ 11:46 PM
NCT ID:
NCT02770651
Eligibility Criteria:
Inclusion Criteria:
* Acute myocardial infarction including ST-segment elevation myocardial infarction (STEMI) or non ST-segment elevation myocardial infarction (NSTEMI) treated with PCI
* Patient ≥ 18 years of age
* Patient judged suitable to receive anti-platelet drugs of ASA and ticagrelor for at least 12 months after the procedure
* The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic, OCT follow up and provides informed consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.
* culprit lesion
Exclusion Criteria:
* The patient has a known hypersensitivity or contraindication to any of the following medications: heparin, abciximab, aspirin, ticagrelor, everolimus, zotarolimus, polymer, platinum chromium, cobalt chromium, contrast media
* Female of childbearing potential unless a pregnancy test is negative or who possibly plan to become pregnant any time after enrollment
* Cardiogenic shock
* Patient with left ventricular ejection fraction \<30%
* Patient with left main disease
* Patient with In-stent restenosis (ISR) at target vessel (either bare metal stent or DES, non-target vessel ISR is permitted)
* Patient with impaired renal function (creatinine \>2.0mg/dL)
* Patient with inadequate OCT images quality due to severe calcification, vessel tortuosity and artifacts
* bifucation lesion needs complex procedure with insert two or more Drug eluting stents.
* lesion length \>30mm
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT02770651
Study Brief:
Protocol Section:
NCT02770651